About Progenics Pharmaceuticals, Inc.

Website
Website
Employees
Employees
51-200 employees View all
Industry
Industry
biotechnology
Location
Location
One World Trade Center,New York,New York,US
Description
Information
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic which completed a two-cohort phase 2 clinical trial and a small molecule imaging agent that has also completed a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra™, an ultra-orphan radiotherapy candidate currently in a phase 2 study under an SPA. Progenics’ first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Ltd., a Valeant Pharmaceuticals International, Inc. company. For additional information, please visit www.progenics.com.

Progenics Pharmaceuticals, Inc. Alternatives

Industry
biotechnology
Industry
biotechnology
Industry
biotechnology
Industry
biotechnology
Industry
biotechnology
Industry
biotechnology

Frequently Asked Questions about Progenics Pharmaceuticals, Inc.

What is Progenics Pharmaceuticals, Inc. email format?

The widely used Progenics Pharmaceuticals, Inc. email format is {f}{last} (e.g. [email protected]) with 83.33% adoption across the company.


What is Progenics Pharmaceuticals, Inc. customer service number?

To contact Progenics Pharmaceuticals, Inc. customer service number in your country click here to find.


Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut

Search Portal

Find countless prospects outside of LinkedIn fast

Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.

Discover the source of our data

Learn more